Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faster aspart vs insulin aspart in type 1 and type 2 diabetes
NCT04588259Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of faster-acting insulin aspart in type 1 diabetes mellitus (T1D), type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Oct 2020; status: completed.
02
Drugs
faster-acting insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04588259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588259.